Immatics (IMTX) Total Non-Current Liabilities (2019 - 2025)
Immatics (IMTX) reported Total Non-Current Liabilities of $41.0 million for Q4 2025, down 28.03% on a YoY basis from $57.0 million in Q4 2024, and down 11.47% sequentially from $46.3 million in Q3 2025.
Immatics (IMTX) Total Non-Current Liabilities (2019 - 2025) Analysis & Trends
Immatics (IMTX) has 7 years of Total Non-Current Liabilities data on file, last reported at $41.0 million in Q4 2025.
- For the quarter ending Q4 2025, Total Non-Current Liabilities fell 28.03% year-over-year to $41.0 million; the trailing twelve-month figure through Dec 2025 stood at $41.0 million (down 28.03% YoY), and the FY2025 full-year result was $39.8 million, down 31.03% from the prior year.
- Total Non-Current Liabilities fell to $41.0 million in Q4 2025, from $46.3 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $146.1 million in Q4 2023 to a low of $41.0 million in Q4 2025.
- A 5-year average of $83.3 million and a median of $78.3 million in 2021 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities soared 76.84% in 2022 and slumped 61.01% in 2024, its largest moves.
- Tracing IMTX's Total Non-Current Liabilities over 5 years: stood at $63.4 million in 2021, then surged by 57.69% to $100.0 million in 2022, then surged by 46.11% to $146.1 million in 2023, then sank by 61.01% to $57.0 million in 2024, then decreased by 28.03% to $41.0 million in 2025.
- Business Quant data shows IMTX's Total Non-Current Liabilities at $41.0 million in Q4 2025, $46.3 million in Q3 2025, and $51.5 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Immatics | 1.14 Bn | 1.14 Bn | - | 41.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 41.00 Mn |
| Sep 30, 2025 | 46.32 Mn |
| Jun 30, 2025 | 51.48 Mn |
| Mar 31, 2025 | 51.87 Mn |
| Dec 31, 2024 | 56.97 Mn |
| Sep 30, 2024 | 75.95 Mn |
| Jun 30, 2024 | 103.55 Mn |
| Mar 31, 2024 | 119.38 Mn |
| Dec 31, 2023 | 146.11 Mn |
| Sep 30, 2023 | 74.62 Mn |
| Jun 30, 2023 | 73.69 Mn |
| Mar 31, 2023 | 83.53 Mn |
| Dec 31, 2022 | 100.00 Mn |
| Sep 30, 2022 | 118.10 Mn |
| Jun 30, 2022 | 138.04 Mn |
| Mar 31, 2022 | 83.44 Mn |
| Dec 31, 2021 | 63.42 Mn |
| Sep 30, 2021 | 66.78 Mn |
| Jun 30, 2021 | 80.61 Mn |
| Mar 31, 2021 | 91.77 Mn |